Editas Medicine Reports Q3 2025 Results and Advances EDIT-401 Toward Human Trials

Reuters

2025/11/10

<a href="https://laohu8.com/S/EDIT">Editas Medicine</a> Reports Q3 2025 Results and Advances EDIT-401 Toward Human Trials

Editas Medicine Inc. reported its third quarter 2025 financial results and provided business updates. The company highlighted preclinical proof-of-concept data presented at the American Heart Association (AHA) and the European Society of Gene and Cell Therapy (ESGCT), demonstrating that its lead candidate, EDIT-401, achieved over 90% reduction in LDL cholesterol levels in non-human primates. In mouse models, the LDL-C reduction was maintained over a three-month study, supporting the durability of the effect. Editas Medicine remains on track to submit an investigational new drug (IND) or clinical trial application $(CTA)$ for EDIT-401 by mid-2026, with initial human proof-of-concept data anticipated by year-end 2026. The company has extended its cash runway into the third quarter of 2027 through proceeds from sales of its common stock under its at-the-market facility and continued financial discipline. Editas also announced participation in the 8th Annual Evercore Healthcare Conference on December 2, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2582873789"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582873789\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582873789?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582873789","market":"nz","top_or_hot":-1,"title":"Editas Medicine Reports Q3 2025 Results and Advances EDIT-401 Toward Human Trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/EDIT\">Editas Medicine</a> Reports Q3 2025 Results and Advances EDIT-401 Toward Human Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Editas Medicine Inc. reported its third quarter 2025 financial results and provided business updates. The company highlighted preclinical proof-of-concept data presented at the American Heart Association (AHA) and the European Society of Gene and Cell Therapy (ESGCT), demonstrating that its lead candidate, EDIT-401, achieved over 90% reduction in LDL cholesterol levels in non-human primates. In mouse models, the LDL-C reduction was maintained over a three-month study, supporting the durability of the effect. Editas Medicine remains on track to submit an investigational new drug (IND) or clinical trial application <a href=\"https://laohu8.com/S/CTA\">$(CTA)$</a> for EDIT-401 by mid-2026, with initial human proof-of-concept data anticipated by year-end 2026. The company has extended its cash runway into the third quarter of 2027 through proceeds from sales of its common stock under its at-the-market facility and continued financial discipline. Editas also announced participation in the 8th Annual <a href=\"https://laohu8.com/S/EVR\">Evercore</a> Healthcare Conference on December 2, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Editas Medicine Reports Q3 2025 Results and Advances EDIT-401 Toward Human Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEditas Medicine Reports Q3 2025 Results and Advances EDIT-401 Toward Human Trials\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-10 20:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/EDIT\">Editas Medicine</a> Reports Q3 2025 Results and Advances EDIT-401 Toward Human Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Editas Medicine Inc. reported its third quarter 2025 financial results and provided business updates. The company highlighted preclinical proof-of-concept data presented at the American Heart Association (AHA) and the European Society of Gene and Cell Therapy (ESGCT), demonstrating that its lead candidate, EDIT-401, achieved over 90% reduction in LDL cholesterol levels in non-human primates. In mouse models, the LDL-C reduction was maintained over a three-month study, supporting the durability of the effect. Editas Medicine remains on track to submit an investigational new drug (IND) or clinical trial application <a href=\"https://laohu8.com/S/CTA\">$(CTA)$</a> for EDIT-401 by mid-2026, with initial human proof-of-concept data anticipated by year-end 2026. The company has extended its cash runway into the third quarter of 2027 through proceeds from sales of its common stock under its at-the-market facility and continued financial discipline. Editas also announced participation in the 8th Annual <a href=\"https://laohu8.com/S/EVR\">Evercore</a> Healthcare Conference on December 2, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4127","symbol_name":"投資銀行業與經紀業","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL49YDmy:1","article_id":"2582873789","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582873789","pubTimestamp":1762776332,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Editas Medicine Inc. reported its third quarter 2025 financial results and provided business updates. The company highlighted preclinical proof-of-concept data presented at the American Heart Association  and the European Society of Gene and Cell Therapy , demonstrating that its lead candidate, EDIT-401, achieved over 90% reduction in LDL cholesterol levels in non-human primates. In mouse models, the LDL-C reduction was maintained over a three-month study, supporting the durability of the effect. Editas Medicine remains on track to submit an investigational new drug  or clinical trial application  for EDIT-401 by mid-2026, with initial human proof-of-concept data anticipated by year-end 2026. The company has extended its cash runway into the third quarter of 2027 through proceeds from sales of its common stock under its at-the-market facility and continued financial discipline. Editas also announced participation in the 8th Annual Evercore Healthcare Conference on December 2, 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4127":"投资银行业与经纪业","EDIT":"Editas Medicine, Inc.","BK4556":"基因编辑","EVR":"Evercore","BK4139":"生物科技"},"translate_title":"Editas Medicine报告2025年第三季度结果并推动EDIT-401进行人体试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EDIT":0.9,"EVR":0.9},"content_text":"Editas Medicine Reports Q3 2025 Results and Advances EDIT-401 Toward Human Trials\n    \n\n        Editas Medicine Inc. reported its third quarter 2025 financial results and provided business updates. The company highlighted preclinical proof-of-concept data presented at the American Heart Association (AHA) and the European Society of Gene and Cell Therapy (ESGCT), demonstrating that its lead candidate, EDIT-401, achieved over 90% reduction in LDL cholesterol levels in non-human primates. In mouse models, the LDL-C reduction was maintained over a three-month study, supporting the durability of the effect. Editas Medicine remains on track to submit an investigational new drug (IND) or clinical trial application $(CTA)$ for EDIT-401 by mid-2026, with initial human proof-of-concept data anticipated by year-end 2026. The company has extended its cash runway into the third quarter of 2027 through proceeds from sales of its common stock under its at-the-market facility and continued financial discipline. Editas also announced participation in the 8th Annual Evercore Healthcare Conference on December 2, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}